Root Financial Partners
RNA icon

Root Financial Partners’s Atrium Therapeutics RNA Stock Holding History

Root Financial Partners’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$25 Buy
+3
New +$35 ﹤0.01% 3778
2026
Q2 		– Sell
-1
Closed -$13 – 3470
2026
Q1 		$13 Buy
+1
New +$14 ﹤0.01% 3451

Other funds holding RNA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Trium Capital
Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
AlphaCentric Advisors
AlphaCentric Advisors San Juan, Puerto Rico $113M AUM 27.37% 1-Year Est. Return

Root Financial Partners's RNA Position: Q3 2026 in Review

Root Financial Partners opened a new position in Atrium Therapeutics (RNA) in Q3 2026: 3 shares worth $25. The stake represents ﹤0.01% of the portfolio and ranks #3778 among its holdings. This is a return to the name: Root Financial Partners previously reported a position in RNA as recently as Q1 2026.

Root Financial Partners first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. 50 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Root Financial Partners held 3 shares of Atrium Therapeutics worth $25 as of Q3 2026.
  • Atrium Therapeutics was a new Root Financial Partners position in Q3 2026.
  • Atrium Therapeutics made up ﹤0.01% of Root Financial Partners's portfolio in Q3 2026, its #3778 holding.
  • Root Financial Partners first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 50 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Root Financial Partners's 13F filing for Q3 2026, filed 21 Oct 2026.